NASDAQ: GENE - Genetic Technologies Limited

半年間の収益性: -4.38%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Genetic Technologies Limited


会社について Genetic Technologies Limited

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

さらに詳しく
It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

IPO date 2005-09-02
ISIN US37185R3075
Industry Life Sciences Tools & Services
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://genetype.com
Цена ао 0.765
1日あたりの価格変動: 0% (0.765)
週ごとの価格変動: 0% (0.765)
月ごとの料金変更: 0% (0.765)
3ヶ月間の価格変動: -0.6494% (0.77)
半年間の価格変動: -4.38% (0.8)
年間の価格変動: -71.67% (2.7001)
3年間の価格推移: -58.2% (1.83)
5年間の価格推移: -79.32% (3.7)
年初からの価格変動: -0.6494% (0.77)

過小評価

名前 意味 学年
P/S 44.57 1
P/BV 186.62 1
P/E 0 0
EV/EBITDA -29.87 0
合計: 1.75

効率

名前 意味 学年
ROA, % -114.22 0
ROE, % -184.98 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0766 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 77604.62 10
収益性 Ebitda, % 87.88 9
収益性 EPS, % 8989 10
合計: 9.2

機関 音量 共有, %
Morgan Stanley 17289 0.45
Rhumbline Advisers 3739 0.1
UBS Group AG 2994 0.08
Wells Fargo & Company 130 0
SIMPLEX TRADING, LLC 18 0



スーパーバイザー 役職 支払い 生年
Mr. Simon Morriss Chief Executive Officer 262.57k
Mr. Carl S. Stubbings BSc Chief Commercial Officer 173.93k
Mr. Kevin Camilleri Chief Executive Officer of EasyDNA 167.85k
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA Consultant 119.53k
Mr. Mark Ziirsen CFO & Company Secretary 1963 (62 年)
Dr. Erika Spaeth Ph.D. Director of Clinical & Scientific Affairs

住所: Australia, Fitzroy, 60-66 Hanover Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://genetype.com